Eli Lilly outpaces Novo in the GLP-1 market with Tirzepatide and emerging blockbusters, signaling future growth. Read more on ...

We came across a bullish thesis on Eli Lilly and Company on Stock Analysis Compilation’s Substack. In this article, we will ...

Eli Lilly (LLY) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some ...

Lilly (LLY) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

In the latest quarter, 7 analysts provided ratings for Eli Lilly LLY +1.30% Get Free Report , showcasing a mix of bullish and ...

Eli Lilly's LLY -0.28% Get Free Report short percent of float has fallen 3.96% since its last report. The company recently reported that it has 7.71 million shares sold short, which is 0.97% of all ...

Breaking Down Analyst Ratings: A Detailed Examination An in-depth analysis of recent analyst actions unveils how financial experts perceive Eli Lilly.

Yahoo Finance Markets and Data Editor Jared Blikre, who also hosts Yahoo Finance's Stocks in Translation podcast, takes a ...

Roche Holding AG's H2 2025 earnings show solid growth in pharma revenues but highlight pipeline struggles and U.S. pricing pressures. Click for my RHHBY update.

Baseline BMI may play a significant role in improving exercise capacity, body weight and BP among patients with HF with ...

Global healthcare stocks have not been this cheap in decades and fund inflows into the sector are picking up, yet the shares remain in the doldrums, highlighting uncertainty over drug pricing policies ...

The sale represents Clever Culture’s fifth engagement with a leading pharma manufacturer, including AstraZeneca, Bristol ...